Previous 10 | Next 10 |
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA ® (adalimumab)...
Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...
Kahn Brothers' 13F portfolio value decreased from ~$788M to ~$743M this quarter. New York Community Bancorp, Citigroup, VOXX International, and ViewRay were increased while decreasing Patterson-UTI Energy during the quarter. The portfolio continues to be very concentrated with the...
BofA Securities has downgraded Organon ( NYSE: OGN ) to neutral from buy following the company's recent Q2 2022 results as there are better opportunities for upside in pharma. The firm also lowered its price target to $37 from $40 (~14% upside based on Thursday's close...
Organon & Co. (OGN) Q2 2022 Earnings Conference Call August 4, 2022 08:30 ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Sandra Milligan - Head, R&...
The following slide deck was published by Organon & Co. in conjunction with their 2022 Q2 earnings call. For further details see: Organon & Co. 2022 Q2 - Results - Earnings Call Presentation
Despite reporting better than expected financials for 2Q 2022, Organon ( NYSE: OGN ), Merck’s ( MRK ) spinoff focused on women’s health and biosimilars, narrowed the range of 2022 revenue guidance, citing the ongoing unfavorable impact of forex rates. O...
Organon press release ( NYSE: OGN ): Q2 Non-GAAP EPS of $1.25 beats by $0.06 . Revenue of $1.59B (flat Y/Y) beats by $60M . Full year 2022 financial guidance ranges updated: Revenues range narrowed to $6.1 billion to $6.3 billion from a prior outlook o...
Second quarter 2022 revenues of $1,585 million Second quarter diluted earnings per share from continuing operations of $0.92 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.25 Both reported and non-GAAP adjusted diluted earnings per share incl...
Organon ( NYSE: OGN ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $1.19 (-30.8% Y/Y) and the consensus Revenue Estimate is $1.53B (-3.8% Y/Y). Over the last 1 year, OGN has beaten EPS est...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...